复发小细胞肺癌的基因组与转录组特征
该研究对54例复发和27例初治小细胞肺癌样本进行全外显子组、全基因组和RNA测序,其中26例为配对样本。复发样本具有铂类和APOBEC突变特征、MYC家族扩增及免疫逃逸机制,初治与复发样本的突变相关新抗原数量无显著差异。研究提示靶向剪接机器、WNT信号和免疫逃逸通路可能发现新的治疗脆弱点。
要点
- 复发SCLC呈现铂类和APOBEC突变特征及MYC家族扩增。
- 初治与复发SCLC的突变相关新抗原中位数分别为86和90(p=0.8)。
- 复发样本存在CD24扩增、IDO1过表达、M2巨噬细胞增多和HLA-E上调等免疫逃逸机制。
核心结论
- 复发小细胞肺癌具有基因组不稳定、WNT和MYC通路失调及剪接异常等特征。
研究设计与样本
- 研究分析了54例复发和27例初治小细胞肺癌样本,采用全外显子组测序(含26例患者配对样本)。
- 部分样本还进行了全基因组测序(n=28)和RNA测序(n=31)。
- 比较了诊断与复发样本在突变特征、基因表达、结构变异、剪接和新抗原谱等方面的差异。
主要发现
- 复发样本具有铂类和APOBEC突变特征,并伴有MYC、MYCL和MYCN扩增。
- 初治和复发样本的突变相关新抗原中位数分别为86和90(p=0.8),TP53是最常产生新抗原的突变基因(占分析样本的48%)。
- 复发样本中观察到CD24扩增、IDO1过表达、M2巨噬细胞增多和HLA-E上调等潜在免疫逃逸机制。
- 初治与复发样本的可变剪接模式存在差异,保留内含子事件在初治样本中显著富集,影响DNA修复、代谢及WNT和MYC通路基因。
临床怎么用
- 复发SCLC的分子特征提示可针对剪接机器、WNT信号和免疫逃逸通路开展后续治疗探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Relapsed SCLC is characterized by treatment resistance and poor outcomes. Genomic and transcriptomic alterations in relapsed SCLC have not been well characterized. We comprehensively profiled relapsed SCLC samples along with patient-matched treatment-naive samples, when available, using whole-exome, whole-genome, and RNA sequencing to describe the molecular landscape of relapsed SCLC. Our goal is to identify potential novel pathways for additional functional validation and eventually novel therapeutic options. METHODS: We analyzed 54 relapsed and 27 treatment-naive SCLC samples using whole-exome sequencing (with 26 patient-matched paired samples). Subsets of the samples were also analyzed through whole-genome sequencing (n = 28) and RNA sequencing (n = 31). Differences in mutational signatures, gene expression, structural variants, splicing, and neoantigen profiles between diagnosis and relapse were investigated. RESULTS: Relapsed SCLC samples had mutation signatures characteristic of platinum and APOBEC mutagenesis. Furthermore, these samples were characterized by MYC, MYCL, and MYCN amplifications. Both treatment-naive and relapsed SCLC samples had high prevalences of mutation-associated neoantigens (median = 86 in treatment-naive and 90 in relapsed SCLC; p = 0.8), and TP53 was the most frequently altered gene to result in a neoantigen (48% of analyzed samples). Potential mechanisms of immune evasion, including amplification of CD24, overexpression of IDO1, increased M2 macrophage presence, and upregulation of HLA-E, were also observed in relapse samples. Differences in alternative splicing patterns were observed between treatment-naive and relapsed small cell samples. Retained intron events were substantially enriched in treatment-naive samples and affected genes involved in DNA repair, metabolism, and the Wingless/Intergrated-1 (WNT) and MYC pathways. CONCLUSIONS: This study highlights the genomic and transcriptomic features of relapsed SCLC. These samples were characterized by genomic instability, WNT and MYC dysregulation, and splicing aberrations. Additional studies targeting the splicing machinery, WNT signaling, and immune evasion pathways could identify novel therapeutic vulnerabilities in SCLC.
引用
- Devarakonda S, Hoang M, Sankararaman S, et al. Genomic and Transcriptomic Features of Relapsed SCLC. J Thorac Oncol. 2026. PMID: 42749049. doi:10.1016/j.jtho.2026.104201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。